当前位置: 首页 > 期刊 > 《美国医学杂志》 > 2007年第2期 > 正文
编号:11417107
Dysfunction of innate immunity and associated pathology in neonates
http://www.100md.com 《美国医学杂志》
     Department of Pediatrics, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    The neutrophils and complement system are the critical elements of innate immunity mainly due to participation in the first line of defense against microorganisms by means of phagocytosis, lysis of bacteria, and activation of naive B-lymphocytes. In this report we provide an overview of the up to date information regarding the neutrophil and complement system's functional ability in newborn infants in association with the maternal conditions that exist during the intrauterine stage, gestational age and post-neonatal pathology. The neonates' capacity to control the neutrophil and complement protein activation process has also been discussed because of the evidence that uncontrolled activation of these immune elements provides a significant contribution to the tissue damage and subsequent pathology. The authors are confident that despite the many unanswered questions this review updates their knowledge and points the need for further research to clarify the role of the age-associated dysfunction of neutrophils and complement system in the infection and inflammation related pathology of newborn infants.

    Keywords: Neonates; Innate immunity; Neutrophils; Complement

    Defense against infection, especially in neonates with no immunological memory and low ability to develop specific antibody to the bacteria, viruses, protozoa, and fungi that they are exposed to during intrauterine and postpartum life is predominantly dependent on innate immunity. Among the elements of innate immunity that includes neutrophils, monocytes, macrophages, dendritic and natural killer cells, and complement,[1] the neutrophils and complement system are the critical first line of host defense against the invading pathogens.[2],[3] Neutrophils participate in the first line of defense against microorganisms, and can contribute significantly to tissue damage and subsequent pathology, over and above that caused by the original infection or injury.[4] The presence of pathogens is detected by the neutrophils through germ line-encoded receptors such as Toll-like receptors (TLR), which recognize the microbe-associated molecular patterns.[5] Chemotaxis of neutrophils toward bacterial (proteins, capsules, cell wall fragments, endotoxin), complement (C5a), chemokines (interleukin-8), and fibrin split products attractants, and opsonization of neutrophils by immunoglobulin (Ig) G or the complement proteins (C3b and C4b) predisposes the ingestion of microorganism (or other cells) by the released lysosomal enzymes and the toxic oxygen radicals, hydrogen peroxide, and peroxynitrite radicals produced in the neutrophils. During phagocytosis, the neutrophils use large quantities of molecular O 2 to generate O 2- and other oxidants via a respiratory burst catalyzed by NADPH oxidase.[6]

    More than 40 proteins of the classical, alternative and mannan-binding lectin pathway of the complement (C) system carry out beneficial innate defense functions by participation in phagocytosis, and cause lysis of bacteria, and activation of naive B-lymphocytes. Activation of the complement cascade results in production of inflammatory mediators (C3a, C5a), opsonization of cells with components (C3b, C4b) for recognition and phagocytosis by macrophages, and formation of membrane attack complex (C5b-9) on target membranes.[7]

    Consequently, the modulation of neutrophil and complement activities constitutes an approach designed to regulate inflammatory responses that have a high potential to destroy target tissue. In this review, the authors attempt to provide an overview regarding neutrophil and complement system dysfunction and activation related risk of infection and inflammation pathology in neonates.

    Neutrophil and complement function in the maternal-fetal interface

    In the developing fetus, the earliest neutrophil progenitors are observed at the end of the first trimester in the multipotent hematopoietic cells but not in the yolk sac blood islands.[8],[9],[10],[11],[12] After the second trimester, the bone marrow becomes the major hematopoietic organ.[13] A variety of perinatal conditions can impair production and functional activity of neutrophils in neonates, such as; pregnancy-induced hypertension was identified as a significant factor for aberrant intrauterine myelopoiesis and the development of neonatal neutropenia.[14] Up to 50% to 80% of neonates born to mothers with preeclampsia, a severe form of pregnancy-related hypertension, develop neutropenia.[14] During the hypertensive gestation, decreased colony-stimulating activity occurs in placental conditioned media[15] and neonates,[16],[17] and this may influence proliferation, maturation, and differentiation of neutrophils.[18] Moreover, increased apoptosis of neutrophils has been observed in neonates whose gestation was complicated by preeclampsia.[19],[20] Autoimmune disease associated as well as transplacentally acquired maternal anti-neutrophil antibodies may cause alloimmune/isoimmune neutropenia in the neonate,[21],[22] and can clinically present with omphalitis, delayed separation of the cord, mild skin infections, fever, or pneumonia in the 1st weeks of life. Maternal diabetes has been identified as a condition that affects the chemotactic activity of cord blood neutrophils.[23],[24] The authors have previously shown that gestational diabetes leads to the impairment of cord blood neutrophil motility and postphagocytic bactericidal capacity independently from the insulin requirement for the maintenance of normoglycemia during pregnancy.[25] In addition, prenatal exposure to magnesium sulfate, a drug that is frequently used for attempted tocolysis in preterm labor contributes to the alteration of neutrophil motility and post-phagocytic bactericidal capacity.[26] The intrauterine induction of chemotactic activity and metabolic oxygenation of neutrophils may predispose to the development of pulmonary hemorrhage early after birth, in extremely low birthweight infants with respiratory distress.[27]

    Equilibrium in the complement system is also important for the maintenance of a normal pregnancy. The normal human pregnancy is associated with evidence of complement activation, as determined by higher concentrations of the anaphylotoxins C3a, C4a and C5a in the maternal circulation.[28] Since the fetus is semiallogenic to the mother, mechanisms have evolved to protect fetal tissue from the maternal immune response. Among these mechanisms is the expression of cell-surface complement regulatory proteins at the maternal-fetal interface.[29] Complement factors do not cross the placenta and the fetus begins synthesizing complement proteins at 6-14 weeks of gestation. The trophoblastic cells express high levels of complement-inhibitory proteins to control the complement-mediated damage.[30] The high levels of complement inhibitory proteins (decay-accelerating factor, membrane cofactor protein, and CD59) that are present in the trophoblasts prevent uncontrolled complement activation that would otherwise lead to fetal injury or death in utero . Antiphospholipid antibody-induced fetal loss is associated with complement C3 activation.[31] In maternal plasma, the concentration of anaphylatoxin (C5a) increases in association with preterm delivery.[32] Elimian et al have shown amniotic fluid complement C3 is of value in the diagnosis of intra-amniotic infection during preterm labor with intact membranes.[33] The upregulation of gene expression for the complement factors has been identified in association with premature rupture of membranes.[34]

    Neutrophils and complement during the neonatal period

    Within the first 24 hours of the neonate's life, the circulating neutrophil count increases abruptly and then gradually stabilizes by 48 to 72 hours.[35] This transient rise in the neutrophil count is paralleled by an increase in the circulating neutrophil progenitors, which gradually decrease over the first weeks of life.[36] Furthermore, cycling rates of hematopoietic cells and absolute numbers of immature and mature circulating neutrophils are elevated in neonates compared with adults.[37],[38] Neutrophil counts at 12 hours after birth range from 7,000 to 15,000/mcL in term infants, and at times are higher in preterm neonates compared with children and adults.[38],[39]

    Complement protein concentrations increase after birth and approximate mean adult values between 6 and 18 months of age.[40] Reference values of C1r, C2, C5, C7, Properdin, and factors D, H, and I and C3a and C5a have been determined in cord blood samples from healthy term newborns.[41] Gestational age dependent reduction of complement activity and its regulation has been reported in prematurely born neonates.[42],[43],[44],[45] The authors have previously shown that in preterm born infants without evidence of infection, the cord blood levels of effective molecule of the complement components are significantly lower than in maternal serum.[46] Despite very low levels of native complement proteins, preterm babies are able to generate remarkable amounts of activation products of the complement cascade.[47] Miyano et al[48] have shown that the C3 activation system seems to be well developed even before week 25 of gestation. They reported that among the complement components, C3d was the most sensitive indicator of placenta inflammation.[48] In a previous study,[49] they authors found increased C5 on day 3-4 of life in infants born prematurely after preterm premature rupture of membranes.

    Neutrophil functional deficiency and associated neonatal pathology

    In general, neonatal neutrophil progenitors have a limited capacity to increase neutrophil production in response to infection, which becomes especially important as preterm born neonates have lower numbers of circulating neutrophils.[50] Neutropenia and depleted neutrophil storage pools have been found to be associated with neonatal bacterial sepsis and are predictive of a poor prognosis.[51],[52],[53],[54] In addition to the quantitative defects, numerous qualitative impairments such as defects in endothelial adherence, transendothelial migration, chemotaxis, phagocytosis, and intracellular killing[55],[56],[57],[58] adversely affect the neonatal neutrophils' capacity to fight infection.[59],[60],[61] This interconnects with larger evidence that newborn infants, especially when delivered prematurely, are at considerable risk for bacterial and fungal infections.[62],[63],[64]

    Neonatal neutrophils have adhesion defects because of their defective expression and storage of CD18/CD11b, a member of the β 2 integrin family of adhesion molecules.[65],[66] The total cellular CD11b is diminished in neonatal neutrophils.[56] The lower functional expression of CD11b on neonatal neutrophils correlates with the defect in neutrophil-endothelial adherence.[67] A possible contributory role of defective CD11b function to neonatal infections is supported by the reports of severe recurrent bacterial infections in patients with leukocyte adhesion deficiency.[68] In addition, L-selectin, with ligands expressed on the endothelial surface mediate neutrophil cell adhesion during inflammation, and although L-selectin is expressed at higher levels on hematopoietic progenitor cells of neonates compared with those of adults,[69] neonatal neutrophils in the human and in animal models have lower levels of L-selectin.[55],[70],[71] Moreover, L-selectin levels decrease during the first 24 to 72 hours of life[50] in association with transient leukocytosis[72] and remain low compared with neutrophils of adults, and are even lower in the neutrophils of premature neonates.[55],[73] The decreased surface expression of L-selectin on neutrophils correlates with their impaired capacity to "roll" on vascular endothelium, a process that is important to the initiation of subsequent adhesive events.[55]

    In addition to the adhesive defects, neutrophils from neonates respond poorly to a variety of inflammatory stimuli[71] due to impaired calcium metabolism[74] and abnormal actin polymerization.[75] The Guanosine triphosphate-binding protein (Rac2), an essential regulator of human neutrophil migration and chemotaxis, is significantly lower in the neutrophil protein lysates isolated from cord blood compared with adult blood.[76] Reduced neutrophil migration has been suggested as a reason for the serious bacterial infections seen in preterm neonates despite antibiotic prophylaxis in the mother.[77]

    In addition to the disadvantages with respect to the phagocytic activity of neutrophils, neonates, especially those born prematurely, have an age-specific diminution of opsonins such as fibronectin, immunoglobulins, and complement including mannose-binding lectin,[78],[79],[80],[81],[82] Deficiency of such opsonins impairs the neutrophils' phagocytic capacity in neonates.[63],[83] Moreover, neutrophils, especially from immature neonates have variable in vitro efficiency in killing certain bacteria.[84] Impaired bactericidal activity of the neonatal neutrophils is associated with lower capacity to activate the respiratory burst and lower concentrations of elastase and lactoferrin in the neutrophil granules,[85], [86] which can also be activated by reactive oxygen species, signaling molecules that eventually lead to apoptosis of target cells. Defects in newborn neutrophil function such as decreased ability to generate O 2- in response to neutrophil stimulation increases susceptibility to infection.[87] Subnormal respiratory burst function and intracellular killing has been observed in children diagnosed with myeloperoxidase, glutathione synthetase, and glucose-6-phosphate dehydrogenase deficiency.[88],[89]

    Dysfunctional inflammatory responses have been implicated in several neonatal inflammatory disorders following infection and/or hypoxia, especially among neonates born prematurely. The mechanism of this association is not clear. However, lower responsiveness to lipopolysaccharide (LPS) stimulation during hypoxia and altered apoptosis may increase the rate of chronic inflammatory disorders in the neonatal population.[90],[91],[92]

    There is evidence that apoptosis is necessary for maintenance of neutrophil homeostasis and elimination of functional neutrophils, and therefore, the resolution of inflammation.[93],[94] Generally, circulating neutrophils undergo apoptosis within 24 to 48 hours of their egress from the bone marrow.[94] Continued presence of neutrophils with functional longevity can be an inciting factor in the pathogenesis of chronic inflammatory disorders.[95],[96] In contrast, prolonged survival of activated neutrophils may promote the elimination of bacteria and further leukocyte recruitment in the presence of severe sepsis.[94],[97]

    Neonatal neutrophils have a constitutive delay in apoptosis[98] that can be explained in part by the decreased functional expression of caspase-3, a common component of several key pathways of apoptosis.[99] Some studies suggest that neonatal neutrophils with prolonged survival retain specific cytotoxic and inflammatory functions and may have the functional capacity to contribute to the pathogenesis of inflammatory disorders[100],[101] such as chronic lung disease.[92],[91] An imbalance between neutrophil elastase and its inhibitors such as serine protease and cathepsin has been also implicated in development of chronic lung disease.[102]

    Complement deficiency and associated neonatal pathology

    It has been shown that complement activation is largely responsible for the neutrophil inflammatory response.[103] However, the consistent deficiencies in complement components and receptors seen in neonates, especially those born prematurely may be associated with different pathology, relative to the neonatal period of life. Lassiter et al showed that diminution of C9 in newborn plasma, which is 10-20% compared with adult values, affects their ability to kill E-coli .[104] The profound C9 deficiency found in neonates' correlates with gestational age and limits the capacity to form membrane attack complex (MAC), and may predispose to severe invasive bacterial infections.[105]

    Different cells synthesize complement proteins such as the complement proteins synthesized and secreted by the type III epithelial cells and alveolar macrophages. Structural and functional similarity between surfactant proteins A and D (SP-A and SP-D) and complement activators including C1q and mannose binding lectin (MBL) has been observed. In addition, both surfactant and MBL structurally belong to the collectin family. Turker et al showed that among preterm neonates with respiratory distress syndrome, poor response to surfactant therapy is associated with lower serum levels of C4 at admission and C4 and C3c on the first day of life.[106] Interestingly, SP-A blocks complement activation (binds to C1q) and therefore, minimizes complement-induced lung damage.[107] Complement activation precedes cytokine release, which may suggest a primary role for complement in the pathophysiology of meconium aspiration syndrome that is a serious condition in newborns, and is associated with a poorly characterized inflammatory reaction. Membrane attack complex is increased substantially in the plasma of neonates with meconium aspiration syndrome and closely correlates with the severity of the lung dysfunction.[108] The development of respiratory distress in preterm born neonates is associated with significantly lower levels of CH50, C3, C4, C3d3 and factor B compared as to infants without lung diseases.[109]

    Studies have shown that complement is activated in the cord blood of neonates born with significant acidosis. The association between acidosis and complement activation is characterized by increasing levels of complement degradation products (C5a, C3a) and MAC in the cord blood.[110] Sonntag et al showed that in infants with fetal acidosis complicated with hypoxic-ischemic encephalopathy, plasma C1q and factor B as well as hemolytic activity of the complement system is decreased because of increased release of the sub-cellular constituents, mostly mitochondrial proteins which bind to C1q and activate the complement cascade in vitro and in vivo.[111] It has been shown that IgG down regulates the complement attack on host tissues by controlling complement binding to target tissues or cells.[112]

    Infection in neonates also induces complement activation through the activation of the alternative complement pathway. As a result, the release of the anaphylatoxin C3a mediates inflammatory reactions such as vasodilatation and an increase in the micro-vascular permeability.[113] Recently reported evidence indicates that complement activation is the pathologic mechanism of injury in the post-hypoxic-ischemic neonatal brain because complement activation participates in the ischemia-reperfusion injury associated with temporary loss of blood flow.[114] Diminished C9 and increased MAC have been reported in the spinal fluid of newborn infants with moderate to severe hypoxic-ischemic encephalopathy.[115] The analysis of post-mortem cerebral tissue showed deposition of C9 on all the neurons, including the morphologically apoptotic neurons.

    The possibility of regulating complement activation to protect tissue damage has been discussed in the literature. Frank et al have reported on the ability of IgG to down regulate complement attack on host tissue by controlling complement binding to target tissues or cells.[112] Their finding becomes pertinent because prematurely born neonates have a poor capacity to control complement activation due to lower levels of circulating IgG,[116],[117] and are therefore more vulnerable to complement-mediated damage of the lung and brain.[43],[44],[45]

    Conclusion

    This review highlights the most prominent results of current research regarding the association between common pathology in newborn infants, and the quantitative and qualitative functional capability of their neutrophils and complement proteins.

    Different maternal conditions that exist during the intrauterine stage and preterm delivery affect myelopoiesis, and neutrophil and complement function in the newborn infant. Neutrophils from neonates, particularly those born prematurely, show dysfunction in chemotaxis, integrin-mediated adhesion, oxygen-dependent and independent microbial killing. In addition, neonatal serum has low opsonization capacity and complement protein deficiency that significantly contributes to the susceptibility and development of serious neonatal infection and inflammation-related morbidity. Moreover, the poor capacity to control spontaneous complement activation makes preterm neonates extremely vulnerable to complement-mediated damage of the lung and brain.

    Further research is needed to better define: (i) the role of neutrophils and complement in neonatal infection and inflammation related pathology, and (ii) the pharmacologic agents that enhance the immune response to infection and safely inhibit uncontrolled complement activation in order to protect against major organ injury.

    References

    1.Marodi L. Neonatal innate immunity to infectious agents. Infect Immun 2006; 74 : 1999-2006. [PUBMED] [FULLTEXT]

    2.Burg ND, Pillinger MH. The neutrophil: function and regulation in innate and humoral immunity. Clin Immunol 2001; 99 : 7-17. [PUBMED] [FULLTEXT]

    3.Zilow EP, Hauck W, Linderkamp O, Zilow G. Alternative pathway activation of the complement system in preterm infants with early onset infection. Pediatr Res 1997; 41 : 334-339. [PUBMED] [FULLTEXT]

    4.Mathison RD, Befus AD, Davison JS, Woodman RC. Modulation of neutrophil function by the tripeptide feG. BMC Immunol 2003; 4 : 3-17. [PUBMED] [FULLTEXT]

    5.Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102 : 2660-2669. [PUBMED] [FULLTEXT]

    6.Segal AW. Structure of the NADPH-oxidase: membrane components. Immunodeficiency 1993; 4 : 167-179. [PUBMED]

    7.Cowell RM, Plane JM, Silverstein FS. Complement Activation Contributes to Hypoxic-Ischemic Brain Injury in Neonatal Rats. J Neuroscie 2003; 23 : 9459-9468.

    8.Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol 2001; 29 : 927-936. [PUBMED] [FULLTEXT]

    9.Tavian M, Robin C, Coulombel L, Peault B. The human embryo, but not its yolk sac, generates lympho-myeloid stem cells: mapping multipotent hematopoietic cell fate in intraembryonic mesoderm. Immunity 2001; 15 : 487-495. [PUBMED] [FULLTEXT]

    10.Migliaccio G, Migliaccio AR, Petti S, Mavilio F, Russo G, Lazzaro D, Testa U, Marinucci M, Peschle C. Human embryonic hemopoiesis: kinetics of progenitors and precursors underlying the yolk sac-liver transition. J Clin Invest 1986; 78 : 51-60. [PUBMED] [FULLTEXT]

    11.Robin C, Ottersbach K, de Bruijn M, Ma X, van der Horn K, Dzierzak E. Developmental origins of hematopoietic stem cells. Oncol Res 2003; 13 : 315-321. [PUBMED]

    12.Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol 2001; 29 : 927-936. [PUBMED] [FULLTEXT]

    13.Kelemen E, Calvo W, Fleidner TM. Atlas of human hemopoietic development, New York: Springer-Verlag; 1979

    14.Koenig JM, Christensen RD. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 1989; 321: 557-562. [PUBMED]

    15.Koenig JM, Christensen RD. The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension. Am J Obstet Gynecol 1991; 165 : 467-473. [PUBMED]

    16.Tsao PN, Teng RJ, Tang JR, Yau KI. Granulocyte colony-stimulating factor in the cord blood of premature neonates born to mothers with pregnancy-induced hypertension. J Pediatr 1999; 135 : 56-59. [PUBMED] [FULLTEXT]

    17.Kocherlakota P, La Gamma EF. Preliminary report: rhG-CSF may reduce the incidence of neonatal sepsis in prolonged preeclampsia-associated neutropenia. Pediatrics 1998; 102 : 1107-1011. [PUBMED] [FULLTEXT]

    18.Speer CP, Johnston RB Jr. Neutrophil function in newborn infants. In Pollin RA, Fox WW, eds. Fetal and Neonatal Physiology . Philadelphia; Pa: WB Saunders; 1998; 1954-1960.

    19.Koenig JM, Chegini N. Enhanced expression of Fas-associated proteins in decidual and trophoblastic tissues in pregnancy-induced hypertension. Am J Reprod Immunol 2000; 44 : 347-349. [PUBMED]

    20.Kuntz TB, Christensen RD, Stegner J, Duff P, Koenig JM. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsia. Pediatr Res 2001; 50 : 743-749. [PUBMED] [FULLTEXT]

    21.Bux J, Jung KD, Kauth T, Mueller-Eckhardt C. Serological and clinical aspects of granulocyte antibodies leading to alloimmune neonatal neutropenia. Transfus Med 1992; 2 : 143-149. [PUBMED]

    22.Rodwell RL, Gray PH, Taylor KM, Minchinton R. Granulocyte colony stimulating factor treatment for alloimmune neonatal neutropenia. Arch Dis Child Fetal Neonatal Ed. 1996; 75 : F57-58.

    23.Lapolla A, Sanzari MC, Zancanaro F, Masin M, Guerriero A, Piva I, Toniato R, Erle G, Plebani M, Fedele D. A study on lymphocyte subpopulation in diabetic mothers at delivery and in their newborn. Diabetes Nutr Metab 1999; 12 : 394-399. [PUBMED]

    24.Mohandes AE, Touraine JL, Osman M, Salle B. Neutrophil chemotaxis in infants of diabetic mothers and in preterms at birth. J Clin Lab Immunol 1982; 8 : 117-120. [PUBMED]

    25.Mehta R, Petrova A. Neutrophil Function in Neonates Born to Gestational Diabetic Mothers. J Perinatol 2005; 25 : 178-181.

    26.Mehta R, Petrova A. Intrapartum Magnesium Sulfate Exposure Attenuates Neutrophil Function in Preterm Neonates. Biol Neonate 2006; 89 : 99-103.

    27.Mehta R, Petrova A. Intrauterine neutrophil activation is associated with pulmonary haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91:F415-418.

    28.Richani K, Soto E, Romero R, Espinosa J, Chaiworapongsa T, Nien JK, Edwin S, Kim YM, Hong JS, Mazor M. Normal Pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med 2005; 17 : 239-245.

    29.Jarvis JN, Moore HT, Fine N, Berry SM. Expression of complement regulatory proteins on fetal blood cells in utero. Biol Neonate 1996; 69 : 225-229. [PUBMED]

    30.Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol 1993; 151 : 1562-1570. [PUBMED] [FULLTEXT]

    31.Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiapwei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 2 : 211-220.

    32.Soto E, Romero R, Richani K, Espinoza J, Nien JK, Chaiworapongsa T, Santolaya-Forgras J, Edwin SS, Mazor M. Anaphylatoxins in preterm and term labor. J Perinatal Med 2005; 33 : 306-313.

    33.Elimian A, Figueroa R, Canterino J, Verma U, Aguero-Rosenfeld M, Tejani N. Amniotic fluid complement C3 as a marker of intra-amniotic infection. Obstet Gynecol 1998; 92 : 72-76.

    34.Tashima LS, Millar LK, Bryant-Greenwood GD. Genes upregulated in human fetal membranes by infection or labor. Obstet Gynecol 1999; 94 : 441-449. [PUBMED] [FULLTEXT]

    35.Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease: I. Reference values for neutrophilic cells. J Pediatr 1979; 95 : 89-99.

    36.Geissler K, Geissler W, Hinterberger W, Lechner K, Wurnig P. Circulating committed and pluripotent haemopoietic progenitor cells, in infants. Acta Haematol 1986;75:18-22. [PUBMED]

    37.Christensen RD, Hill HR, Rothstein G. Granulocytic stem cell (CFUc) proliferation in experimental group B streptococcal sepsis. Pediatr Res 1983; 17 : 278-280.

    38.Koenig JM, Luttge B, Benson NA, Christensen RD. Cell cycle status of CD34 + cells in human fetal bone marrow. Early Hum Dev 2001; 65 : 159-163. [PUBMED] [FULLTEXT]

    39.Mouzinho A, Rosenfeld CR, Sanchez PJ, Risser R. Revised reference ranges for circulating neutrophils in very-low-birth-weight neonates. Pediatrics 1994; 94 : 76-82.

    40.Crockett M. Physiology of the neonatal immune system. J Obstetr Gynecol Neonatal Nur 1995; 24 : 627-634.

    41.Sonntag J, Brandenburg U. Polzehl D, Strauss E, Vogel E. Dudenhausen JW, Obladen M. Complement system in healthy term newborns: reference values in umbilical cord blood. Pediatr Dev Pathol 1998; 1 : 131-135.

    42.Huffaker J, Witkin SS, Cutler L, Druzin ML, Ledger WJ. Total complement activity in maternal sera, amniotic fluids and cord sera in women with premature labor, preterm rupture of membranes or chorioamnionitis. Surg Gynecol Obstet 1989; 168 : 397-401.

    43.Schelonka RL, Infante AJ. Neonatal immunology. Semin Perinatol 1998; 22 : 2-14.

    44.Davies J, Turner M, Klein N. The role of the collectin system in pulmonary defense. Paediatr Respir Rev 2001; 2 : 70-75.

    45.Watford W, Wright JR, Hester CG, Jiang H, Frank MM. Surfactant protein A regulates complement activation. J Immunol 2001; 167 : 6593-6600.

    46.Petrova A, Hanna N, Mehta R. Gestational age related maternal-fetal-neonatal humoral immunity. J Applied Research 2004; 4 : 44-49.

    47.Zilow EP, Hauck W, Linderkamp O, Zilow G. Alternative pathway activation of the complement system in preterm infants with early onset infection. Pediatr Res 1997; 41 : 334-339.

    48.Miyano A, Nakayama M, Fujita T, Kitajima H, Imai S, Shimizu A. Complement activation in fetuses: assessment by the levels of complement components and split products incord blood. Diagn Immunol 1987; 5 : 320-327.

    49.Petrova A, Mehta R. Innate Immunity in Mothers and their Newborn Infants during Preterm Premature Rupture of Membranes. J Applied Research 2005; 5 : 282-288.

    50.Christensen RD. Developmental changes in pluripotent hematopoietic progenitors. Early Hum Dev 1988; 16 : 195-205.

    51.Mease AD. Tissue neutropenia: the newborn neutrophil in perspective. J Perinatol 1990; 10 : 55-59.

    52.Cairo MS, Rucker R, Bennetts GA, Hicks D, Worcester C, Amlie R, Johnson S, Katz J. Improved survival of newborns receiving leukocyte transfusions for sepsis. Pediatrics 1984; 74 : 887-892.

    53.Christensen RD, Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr 1980; 96 : 316-318.

    54.Baley JE, Stork EK, Warkentin PI, Shurin SB. Neonatal neutropenia. Am J Dis Child 1988; 142 : 1161-1166.

    55.Anderson DC, Abbassi O, Kishimoto TK, Koenig JM, McIntire LV, Smith CW. Diminished lectin-, epidermal growth factor-, complement binding domain- cell adhesion molecule-1 on neonatal neutrophils underlies their impaired CD18-independent adhesion to endothelial cells in vitro. J Immunol 1991; 146 : 3372-3379.

    56.Abughali N, Berger M, Tosi MF. Deficient total cell content of CR3 (C11b) in neonatal neutrophils. Blood 1994; 83 : 1086-1092.

    57.Ramamoorthy C, Kovarik WD, Winn RK, Harlan JM, Sharar SR. Neutrophil adhesion molecule expression is comparable in perinatal rabbits and humans. Anesthesiology 1997; 86 : 420-427.

    58.Christensen RD. Neutrophil kinetics in the fetus and neonate. Am J Pediatr Hematol Oncol 1989; 11 : 215-223.

    59.al-Mulla ZS, Christensen RD. Neutropenia in the neonate. Clin Perinatol 1995;22: 711-739.

    60.Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000; 110 : 18-28.

    61.Anderson DC. Neonatal neutrophil dysfunction. Am J Pediatr Hematol Oncol 1989; 11 : 224-226.

    62.Christensen RD. Granulocytopoiesis in the neonate and fetus. Trans Med Rev 1990; 4 : 8-13.

    63.Kapur R, Yoder MC, Polin RA. Developmental immunology. In Fanaroff AA, Martin RJ, eds. Neonatal-perinatal medicine St. Louis: Mosby; 2001. p. 676-706.

    64.Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: W.B. Saunders, 2001; 25-138.

    65.Kim SK, Keeney SE, Alpard SK, Schmalstieg FC. Comparison of L-selectin and CD11b on neutrophils of adults and neonates during the first month of life. Pediatr Res 2003; 53 : 132-136.

    66.Graf JM, Smith CW, Mariscalco MM. Contribution of LFA-1 and Mac-1 to CD18-dependent neutrophil emigration in a neonatal rabbit model. J Appl Physiol 1996; 80 : 1984-1992.

    67.Anderson DC, Freeman KL, Heerdt B, Hughes BJ, Jack RM, Smith CW. Abnormal stimulated adherence of neonatal granulocytes: impaired induction of surface Mac-1 by chemotactic factors or secretagogues. Blood 1987; 70 : 740-750.

    68.Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 1987; 38 : 175-194.

    69.Koenig JM, Baron S, Luo D, Benson NA, Deisseroth AB. L-selectin expression enhances clonogenesis of CD34 + cord blood progenitors. Pediatr Res 1999; 45 : 867-870.

    70.Rebuck N, Gibson A, Finn A. Neutrophil adhesion molecules in term and premature infants: normal or enhanced leucocyte integrins but defective L-selectin expression and shedding. Clin Exp Immunol 1995; 101 : 183-189.

    71.Koenig JM, Simon J, Anderson DC, Smith E, Smith CW. Diminished soluble and total cellular L-selectin in cord blood is associated with its impaired shedding from activated neutrophils. Pediatr Res 1996; 39 : 616-621.

    72.Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease: I. Reference values for neutrophilic cells. J Pediatr 1979; 95 : 89-98.

    73.Kim SK, Keeney SE, Alpard SK, Schmalstieg FC. Comparison of L-selectin and CD11b on neutrophils of adults and neonates during the first month of life. Pediatr Res 2003; 53 : 132-136.

    74.Weinberger B, Laskin DL, Mariano TM, Sunil VR, DeCoste CJ, Heck DE, Gardner CR, Laskin JD. Mechanisms underlying reduced responsiveness of neonatal neutrophils to distinct chemoattractants. J Leukoc Biol 2001; 70 : 969-976.

    75.Harris MC, Shalit M, Southwick FS. Diminished actin polymerization by neutrophils from newborn infants. Pediatr Res 1993; 33 : 27-31.

    76.Meade VM, Barese CN, Kim C, Njinimbam CG, Marchal CC, Ingram DA, Clapp DW, Dinauer MC, Yoder MC. Rac2 concentrations in umbilical cord neutrophils. Biol Neonate 2006; 90 : 156-159.

    77.Glasner A, Egger G, Winter R. Impaired whole-blood polymorphonuclear leukocyte migration as a possible predictive marker for infections in preterm premature rupture of membranes. Infect Dis Obstet Gynecol 2001; 9 : 227-232.

    78.Baker CJ, Rench MA, Noya FJ, Garcia-Prats JA. Role of intravenous immunoglobulin in prevention of late-onset infection in low-birth-weight neonates. The Neonatal IVIG Study Group. Rev Infect Dis 1990; 12 : S463-468.

    79.Dyke MP, Forsyth KD. Plasma fibronectin levels in extremely preterm infants in the first 8 weeks of life. J Paediatr Child Health 1994; 30 : 36-39.

    80.Kallman J, Schollin J, Schalen C, Erlandsson A, Kihlstrom E. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1998; 78 : F46-50.

    81.Summerfield JA, Sumiya M, Levin M et al. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314 : 1229-1232.

    82.Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2 : 1236-1239.

    83.Lewis DB, Wilson CB. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant Philadelphia: W.B. Saunders, 2001; 25-138.

    84.Hill HR. Biochemical, structural and functional abnormalities of polymorphonuclear leukocytes in the neonate. Pediatr Res 1987; 22 : 375-382.

    85.Kjeldsen L, Sengelov H, Lollike K, Borregaard N. Granules and secretory vesicles in human neonatal neutrophils. Pediatr Res 1996; 40 : 120-129.

    86.Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, Lee K, Goldmann D, Thorne GM. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999; 104 : 1327-1333.

    87.Clifford CB, Slauson DO, Neilsen NR, Suyemoto MM, Zwahlen RD, Schlafer DH. Ontogeny of inflammatory cell responsiveness. Inflammation 1989; 13 : 221-231

    88.Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 1981; 95 : 293-301.

    89.Lakshman R, Finn A. Neutrophil disorders and their management. Clin Pathol 2001; 54 : 7-19.

    90.Molloy EJ, O'Neill AJ, Doyle BT, Grantham JJ, Taylor CT, Sheridan-Pereira M, Fitzpatrick JM, Webb DW, Watson RW. Effects of heat shock and hypoxia on neonatal neutrophil lipopolysaccharide responses: altered apoptosis, Toll-like receptor-4 and CD11b expression compared with adults. Biol Neonate 2006; 90 : 34-39.

    91.Oei J, Lui K, Wang H, Henry R. Decreased neutrophil apoptosis in tracheal fluids of preterm infants at risk of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2003; 88 : F245-249.

    92.Kotecha S, Mildner RJ, Prince LR, Vyas JR, Currie AE, Lawson RA, Whyte MK. The role of neutrophil apoptosis in the resolution of acute lung injury in newborn infants. Thorax 2003; 58 : 961-967.

    93.Burg ND, Pillinger MH. The neutrophil: function and regulation in innate and humoral immunity. Clin Immunol 2001; 99 : 7-17.

    94.Haslett C. Granulocyte apoptosis and inflammatory disease. Br Med Bull 1997; 53 : 669-683.

    95.Haslett C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999; 160 : S5-S11.

    96.Speer CP. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79 : 205-209.

    97.Dransfield I, Stocks SC, Haslett C. Regulation of cell adhesion molecule expression and function associated with neutrophil apoptosis. Blood 1995; 85 : 3264-3673.

    98.Allgaier B, Shi M, Luo D, Koenig JM. Spontaneous and Fas-mediated apoptosis are diminished in umbilical cord blood neutrophils compared with adult neutrophils. J Leukoc Biol 1998; 64 : 331-336.

    99.Luo D, Schowengerdt Jr KO, Stegner JJ, May Jr WS, Koenig JM. Decreased functional caspase-3 expression in umbilical cord blood neutrophils is linked to delayed apoptosis. Pediatr Res 2003; 53 : 859-864.

    100.Koenig JM, Stegner JJ, Schmeck AC, Saxonhouse MA, Kenigsberg LE. Neonatal neutrophils with prolonged survival exhibit enhanced inflammatory and cytotoxic responsiveness. Pediatr Res 2005; 57 : 424-429.

    101.Stegner JJ, Schmeck A, Kenigsberg L, Saxonhouse M, Koenig JM. Umbilical cord blood neutrophils with prolonged survival retain their capacity to elaborate reactive oxygen intermediates. Pediatr Res 2004; 55 : 390A.

    102.Yasumatsu R, Altiok O, Benarafa C, Yasumatsu C, Bingol-Karakoc G, Remold-O'Donnell E, Cataltepe S. SERPINB1 upregulation is associated with in vivo complex formation with neutrophil elastase and cathepsin G in a baboon model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2006; 291 : L619-627.

    103.Castellheim A, Pharo A, Fung M, Saugstad OD, Mollnes TE. Complement C5a is a key mediator of meconium-induced neutrophil activation. Pediatr Res 2005; 57 : 242-247.

    104.Lassiter HA. Complement factor 9 deficiency in serum of human neonates. J Infect Dis 1992; 166 : 53-57.

    105.Hogasen AK, Overlie I, Hansen TW, Abrahamsen TG. Finne PH, Hogasen K. The analysis of the complement activation product SC5b9 is applicable in neonates in spite of their profound C9 deficiency. J Perinat Med 2000; 28 : 39-48.

    106.Turker G,Koksal N. Complement 4 levels as early predictors of poor response to surfactant therapy in respiratory distress syndrome. Am J Perinatol 2005; 22 : 149-154.

    107.Watford WT, Wright JR, Hester CG, Jiang H, Frank MM. Surfactant protein A regulates complement activation. J Immunol 2001; 167 : 6593-6600.

    108.Lindenskov PH, Castellheim A, Aamodt G, Saugstad OD. Mollnes TE. Complement activation reflects severity of meconium aspiration syndrome in newborn pigs. Pediatr Res 2004; 56 : 810-817.

    109.Miyano A, Kitajima H, Fujiwara F, Nakayama M, Fujita T, Fujimura M, Takeuchi T, Shimizu A. Complement function and the synthesis of lung surfactant may be a regulation which preterm infants have in common. Complement Inflamm 1991; 8 : 320-327.

    110.Hecke F, Hoehn T, Strauss E, Obladen M, Sonntag J. In-vitro activation of complement system by lactic acidosis in newborn and adults. Mediators Inflamm 2001; 10 : 27-31.

    111.Sonntag J, Wagner MH, Strauss E, Obladen M. Complement and contact activation in term neonates after fetal acidosis. Arch Dis Child Fetal Neonatal Ed 1998; 78 : F125-F128.

    112.Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res 2000; 22 : 137-146.

    113.Zilow G, Zilow EP, Burger R, Linderkamp O. Complement activation in newborn infants with early onset infection. Pediatr Res 1993; 34 : 199-203.

    114.Lassiter A. The role of complement in neonatal hypoxic-ischemic cerebral injury. Clin Perinatol 2004; 31 : 117-127.

    115.Schultz SJ, Aly H, Hasanen BM, Khashaba MT, Lear SC, Bendon RW, Gordon LE, Feldholff PW, Lassiter HA. Complement component 9 activation, consumption and neuronal deposition in the post-hypoxic-ischemic central nervous system of human newborn infants. Neurosci Lett 2005; 378 : 1-6.

    116.Miletic VD, Frank MM. Complement-immunoglobulin interactions. Curr Opin Immunol 1995; 7 : 41-47.

    117.Landor M. Maternal-fetal transfer of immunoglobulins. Ann Immunol 1995; 74 : 279-283.(Petrova Anna, Mehta Rajeev)